Technology Transfer      


Quarterly newsletter from the UMDNJ Office of Technology Transfer and Business Development 

 

 

 

 

 

 

  April 2012
In This Issue
Upcoming Events
Technology Spotlight: Cancer Treatment Regimen Library
Spin-Off Company Highlight: TRIM-edicine, Inc
Recently Issued U.S. Patents
Recent License Agreements and Amendments

Upcoming Events


Office of Technology Transfer and Business Development presents The Value of Intellectual Property: Research, Innovation & Entrepreneurship 
RWJMS
Department of Family Medicine and Community Health  
May 8, 2012

Christoper Izzo, Director of Legal Management and Patent Attorney at the OTTBD presents on licensing, patents and ownership of data and intellectual property to graduate students in an ethics class
Friday May 10, 2012
10:00am
  

BIONJ International BioPartnering Conference

The Westin Princeton at Forrestal Village
May 10 - 11, 2012
details

Create a New Revenue Stream by Supporting On-Campus App Developers
Thursday, May 24, 2012 1:00pm -2:00pm

Live Webinar Viewing at the OTTBD

1 World's Fair Drive

Somerset, NJ

Please RSVP to OTTBD@umdnj.edu 

details 

   

Promoting Objectivity in Research: Conflict of Interest
Judith Neubauer, Ph.D.
May 31, 2012
2:00pm - 3:00pm
Location: TBD, UMDNJ Newark Campus
Contact OTTBD@umdnj.edu  for details 
 

  

2012 BIO International Convention June 18-21, 2012
Boston, MA
details  
News Flashes

Available antibodies and animal models?    

The UMDNJ Office of Technology Transfer and Business Development is currently organizing a list of antibodies and animal models available for licensing to various companies that have expressed interest. If you have any antibodies or animals models that you would be interested in licensing, please contact the OTTBD (OTTBD@umdnj.edu) to request additional information and to fill out an intake form.

 

INTERNSHIP ANNOUNCEMENT: Attention postdoctoral trainees and graduate students interested in alternative careers

The OTTBD is pleased to announce the fourth year of its internship program where postdoctoral trainees and graduate students interested in pursuing alternative careers in Intellectual Property Law, Business Development, and/or Academic Technology Transfer are invited to apply for the internship program. For additional application details, please email Raesu@umdnj.edu.  

 

Create a New Revenue Stream by Supporting On-Campus App Developers.

The explosion in sales of smart phones and tablets has given rise to a market for mobile apps that forecasters predict will exceed $25 billion by 2015. For university TTOs, this presents a tremendous opportunity for new revenues as well as new relationships with the hundreds of students and faculty creating apps on campus. A small but growing number of universities have identified this growing trend as a way to enhance TTO revenue and better serve their researchers - and now's your chance to join them. Technology Transfer Tactics Distance Learning Division has secured two top-level university tech transfer professionals with first-hand experience in app development, support, and negotiations with Apple and Google. For additional details on the webinar: click here.

*There will be a live viewing of this webinar in the UMDNJ OTTBD. Details can be found in the "Upcoming Events" Section of this newsletter.

 

Biosearch Technologies Acquires Worldwide Rights to UMDNJ Non-FRET Probes Patents

Biosearch Technologies, Inc. (Biosearch), a leading supplier of sophisticated oligonucleotide components to the rapidly growing molecular diagnostics industry, announced that the company has acquired worldwide rights from the University of Medicine and Dentistry of New Jersey (UMDNJ) to United States Patent 6,150,097, titled "Nucleic Acid Detection Probes Having Non-FRET Fluorescence Quenching and Kits and Assays Including Such Probes," as well as counterpart patents in Australia, Canada, France, Germany, Great Britain, Italy, and Japan, that disclose and claim, among other thing, probes having quenchers and fluorophores that are not FRET pairs, as well as their use. For full article: click here.


Dr. David Alland Receives Grand Challenges Tuberculosis Biomarkers Grant

Dr. David Alland, professor of medicine, chief of infectious diseases, and director of the Center for Emerging and Re-Emerging Pathogens at UMDNJ-New Jersey Medical School, will receive a tuberculosis (TB) biomarkers grant awarded by the Bill & Melinda Gates Foundation's Grand Challenges in Global Health program, an initiative which seeks to overcome persistent bottlenecks in creating new tools that can radically improve health in the developing world. For full article: click here.   

 

Vincent Smeraglia, Executive Director

Vince Smeraglia, Esq., previously Director of the UMDNJ Office of Technology Transfer and Business Development is now the Executive Director of The Office Technology  Transfer and Business Development.

 

The Office of Technology Transfer and Business Development     

The UMDNJ Office of Patents and Licensing (OPL) has changed its name! We are now referred to as the Office of Technology Transfer and Business Development (OTTBD) to better reflect the broad mission of the office within the university. For all e-mail communications: OTTBD@umdnj.edu   

 

 

Technology Spotlight:   

Cancer Treatment Regimen Library  

Adam Lisi, Pharm.D.
Susan Goodin, Pharm.D., BCOP
UMDNJ's Cancer Treatment Regimen Library Database for the standard of cancer care consists of over 400 unique cancer treatment regimens, which treat over 100 different cancer categories. Each cancer treatment regimen in the Library has the following components: chemotherapy agents, the associated supportive care agents, hydration fluids, recommended lab and diagnostic tests, CTCAE toxicities, clinical research references, and an integrated chemotherapy-specific clinical decision support. The clinical decision support checks the patient's electronic medical record (EMR) for any specific abnormal conditions. If an abnormal condition is present, a notification will alert the physician upon order entry. This notification may prompt the ordering physician to modify current chemotherapy. The rule and notification function sets this cancer treatment regimen library apart from both the currently available libraries from the major EMR software vendors and many other major cancer treatment centers.

 

The UMDNJ Cancer Treatment Regimen Library, developed by Dr. Adam Lisi, Pharm.D. in collaboration with Dr. Susan Goodin, Pharm.D., BCOP, is managed by The Cancer Institute of New Jersey, which represents the standard of cancer care as a National Cancer Institute Comprehensive Cancer Center in an outpatient setting. Each cancer treatment regimen report is reviewed and approved by a multi-disciplinary team, which includes the tumor specific oncologists, pharmacists, and nurses before entry into the Cancer Treatment Regimen Library Database. The Cancer Treatment Regimen Library is constantly updated with changes in standard of cancer care for a particular cancer treatment regimen or when a new cancer treatment regimen is added to the Cancer Treatment Regimen Library Database thus reflecting the ever changing standard of cancer care.

 

"Our goal is to form alliances with major EMR [Electronic Medical Record] software vendors and cancer treatment centers globally to license this important technology on an ongoing basis," said Vincent Smeraglia Executive Director of the Office of Technology Transfer and Business Development at UMDNJ.

 

For more information, contact the UMDNJ Office of Technology Transfer and Business Development: OTTBD@umdnj.edu
.

Spin-Off Company Highlight:

TRIM-edicine, Inc

  

TRIM-edicine, Inc. (http://trim-edicine.com/) is an early-stage, privately held biotechnology company engaged in the development of novel biopharmaceutical products for the treatment of several important unmet medical needs, including oral healthcare, dermal wounds, ischemia/reperfusion injury, sports medicine and muscular dystrophy. The company is built around a core of protein therapeutic approaches that involve novel proteins with remarkable biological properties. These unique proteins target a variety of cellular pathways that are altered in numerous disease states. R&D efforts at TRIM-edicine focus on providing proof-of-concept support to validate the technology and facilitate partnerships with various established companies in the biomedical field.

  

Platform technologies include protein therapeutics for tissue repair in chronic disease or traumatic injury, biologics for regenerative medicine for genetic disorders involving compromised cellular plasticity and repair capacity, and bioactive peptides for pharmaceutical and cosmeceutical applications.   

 

Leadership Team:

 

Peter Lobel, PhDDr. Jianjie Ma, Ph.D., is the Founder and President of TRIM-edicine. He is currently a University Professor at Robert Wood Johnson Medical School (RWJMS), and Director of a joint Graduate Program in Physiology and Integrative Biology between RWJMS and Rutgers University. Dr. Ma obtained his bachelor's degree in Physics from Wuhan University in China and Ph.D. in Physiology and Biophysics at Baylor College of Medicine. He serves on the editorial board of several major scientific journals and has authored or co-authored over 100 articles in peer-reviewed scientific journals. He is an Established Investigator from the American Heart Association, and frequently serves as a study section member for the National Institutes of Health. His research interests are in gene discovery and protein therapy in geriatric medicine, tissue repair, muscular dystrophy, cardiovascular disease, and cancer biology.


Dr. Noah Weisleder, Ph.D., received his B.S. in Biotechnology and Molecular Biology from Worcester Polytechnic Institute and a Ph.D. in Cell Biology from Baylor College of Medicine. He conducted his postdoctoral studies at Robert Wood Johnson Medical School where he is now an Assistant Professor in the Department of Physiology and Biophysics. During this time, Dr. Weisleder has published dozens of peer-reviewed publications or book chapters in the fields of muscle physiology, cardiovascular disease, cytoskeletal dynamics, membrane repair and cellular calcium homeostasis in normal physiology and disease states. Additionally, he is an inventor on two US patents, nine published US patent applications and numerous international patent applications. These inventions became the basis for formation of TRIM-edicine, a biotechnology company developing protein therapeutics targeting regenerative medicine applications, where Dr. Weisleder is a Co-Founder and Chief Scientific Officer. He has received a Fellowship from the American Heart Association, a Pathway to Independence Award from the National Institutes of Health and the 2011 Kauffman Foundation Outstanding Postdoctoral Entrepreneur Award. 

   

For more information on TRIM-edicine and partnership opportunities, contact the UMDNJ Office of Technology Transfer and Business Development: OTTBD@umdnj.edu. 

Recently Issued U.S. Patents 
Cancer biomarker genes and gene products and methods for using the same; (Gary Goldberg, Yongquan Shen), US Patent # 8,114,593 Using gene expression analysis, specific biomarker genes and gene products have been identified which are activated in transformed cells, but suppressed in nontransformed cells; or suppressed in transformed cells, but activated in transformed cells affected by Contact Normalization. Thus, the present invention features compositions and methods for detecting, diagnosing, treating and prognosing cancer. 
 
Anti-mitotic anti-proliferative compounds; (William Welsh, Youyi Peng, Xin Wang, Susan Keenan, Qiang Zhang, Sonia Arora), US Patent # 8,143,299 Substituted triazole compounds and pharmaceutical compositions thereof are presented. Also presented are methods for treating a pathology linked to a hyperproliferative disorder by administering the substituted triazole compounds to a patient in need thereof.

For additional information on any of the above issued patents, please contact the Office of Technology Transfer and Business Development at OTTBD@umdnj.edu.  

Recent License Agreements and Amendments

Extension to the Option Agreement to exclusively license novel interferon-associated technology developed at UMDNJ.

 

Amendment to the exclusive license agreement to a spin-off company, to technology developed at UMDNJ.

 

License agreement with Biosearch Technologies to patents covering "non-FRET" nucleic acid probe technology. 

 

Nonexclusive license agreement with Abcam to sell an F actin antibody developed at UMDNJ.
UMDNJ Office of  Technology Transfer and Business Development

  

UMDNJ Office of Technology Transfer and Business Development Staff

Top left to right: Robert Bzdek, Christopher Izzo, Vince Smeraglia

Bottom left to right: Laura Schepps, Norell Hadzimichalis, Tejal Talati, Anya Nikiforova, Susan Rae, Tania Litvin-Vechnyak (Not shown: Lilly Cohen, Mona Daniels, Sue Dolci,  Nicole O'Hara)

 

  

1 World's Fair Drive; Suite 2100

Somerset, NJ 08873

P: 732-235-9350; F: 732-235-9358

Email: OTTBD@umdnj.edu

UMDNJ OTTBD website

 

 View our profile on LinkedIn Follow us on Twitter

    

 

For suggestions on future newsletter content, including upcoming events, news flashes, and articles please email OTTBD@umdnj.edu